Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
The idiotype of the immunoglobulin on a given B cell malignancy (Id) can serve as a clonal
marker, and a previous pilot study in lymphoma patients has demonstrated that autologous Id
protein can be formulated into an immunogenic, tumor specific antigen by conjugation to a
carrier protein (KLH) and administration with an emulsion-based adjuvant.
The objectives of this study are: 1) to evaluate feasibility and toxicity of new vaccine
formulations, and 2) to evaluate cellular and humoral immune responses against the unique
idiotype of the patient's lymphoma.
The goal of this study is to treat patients with follicular lymphomas to complete remission
or minimal residual disease with chemotherapy. Six to twelve months after completion of
chemotherapy, in an effort to reduce the relapse rate (by eradicating microscopic disease
resistant to chemotherapy), patients will receive one of two new formulations of an
autologous Id vaccine.
Primary Purpose: Treatment
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|